

November 11, 2024

UPDATE: Anticipated Allocation Changes for U.S. IV Products – Hurricane Impact on Baxter’s North Cove, NC Facility

Dear Valued Customer:

To help support our customers’ ability to plan for patient care, Baxter is sharing its expectations for increases in allocation levels across several IV product codes for direct customers and distributors in the U.S. These updates are in follow-up to Baxter’s communication on Oct. 9, 2024, regarding product code allocations in response to Hurricane Helene’s impact on our North Cove, NC facility. **This communication is a preview of anticipated changes through the end of 2024; the full list of allocation adjustments will be communicated to customers ahead of the expected effective dates.**

Barring any unanticipated developments in Baxter’s ability to resume production of IV solutions manufacturing lines at North Cove over the coming weeks, Baxter intends to implement the following adjustments to key IV allocations:

Code	Description	NDC	Current Allocation Levels	Anticipated Allocation Levels		
			11-Nov	25-Nov	16-Dec	30-Dec
2B1324X	SOD CHLOR 0.9% INJ USP VIAFLEX 1000ML MIGRATED	00338-0049-04	60%	80%	100%	100%
2B1323Q	SOD CHLOR 0.9% INJ USP VIAFLEX 500ML MIGRATED	00338-0049-03	60%	80%	100%	100%
2B1322Q	SOD CHLOR 0.9% INJ USP VIAFLEX 250ML MIGRATED	00338-0049-02	60%	80%	100%	100%
2B0064X	DEXTROSE 5% INJECTION USP 1000ML MIGRATED	00338-0017-04	60%	80%	100%	100%
2B0063Q	DEXTROSE 5% INJECTION USP 500ML MIGRATED	00338-0017-03	60%	80%	100%	100%
2B0062Q	DEXTROSE 5% INJECTION USP 250ML MIGRATED	00338-0017-02	60%	80%	100%	100%
2B2324X	LACTATED RINGER INJECTION, USP VIAFLEX 1000ML	00338-0117-04	40%	40%	80%	100%
2B2323Q	LACTATED RINGER INJ, USP VIAFLEX 500ML	00338-0117-03	40%	40%	40%	100%
2B2322Q	LACTATED RINGER INJ, USP VIAFLEX 250ML	00338-0117-02	60%	60%	60%	100%
2B2544X	PLASMA-LYTE A INJECTION PH 7.4 MULTIPLE	00338-0221-04	40%	60%	90%	100%
2B7127	0.9% SOD.CHL.IRRIGATION USP 3000ML UROMATIC	00338-0047-47	40%	40%	40%	40%
2B7487	LACTATED RINGERS IRRIGATION, 3000ML ARTHROMATIC	00338-0137-27	40%	40%	40%	100%

Please note that there is a typical 1 to 2-week lag time for product to flow through the full distribution network after allocation changes are implemented.

The anticipated allocation changes communicated in this letter represent adjustments to high-demand IV solution codes only and are based on 1) the current and projected status of our North Cove remediation efforts, 2) our expectations regarding our ability to reallocate capacity from other Baxter facilities, and 3) temporary importation on certain products.

Baxter’s top priority is helping to ensure reliable product supply for our customers and patients, while resuming production at North Cove and continuing to support our employees in the communities impacted by Hurricane Helene. We understand the critical importance of supply continuity and are committed to continuing transparent and proactive communications with you.



Conservation efforts remain essential to supplement allocation levels. For medical information, support or questions regarding conservation strategies, please contact MedInfo@Baxter.com, call 1-800-933-0303, or visit [Hurricane Helene Conservation and Medical Information Resources | Baxter](#).

Thank you for your patience and partnership as we navigate this difficult situation.

Sincerely,

Mary Henson
General Manager, U.S. and Canada
Infusion Therapies and Technologies